Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

NCT01585194 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01585194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01585194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2012
Completion date
May 14, 2024
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma, stage iv uveal melanoma ajcc v7